Nilutamide

  • CAS No.: 63612-50-0
  • Purity: 99%
Contact us

Quality products?make an important contribution to long-term revenue and profitability. Manufacturer supply high quality Nilutamide 63612-50-0 with GMP standards

1.What is the Nilutamide ?

Crystalline Solid

Nilutamide is a non-steroidal anti-androgen similar in potency to the acyclic urea flutamide (55) and useful in the management of prostatic carcinoma.

2.What is the CAS number for Nilutamide ?

The CAS number of Nilutamide is 63612-50-0.

3.What are another words for Nilutamide ?

Synonyms?for?Nilutamide 63612-50-0:2,4-Imidazolidinedione,5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-;1-(3-Trifluoromethyl-4-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione;1-(3-Trifluoromethyl-4-nitrophenyl)-4,4-dimethylimidazoline-2,5-dione;Anandron;Nilandron;Nilandrone;RU 23908;RU 23908-10;

4.What is Nilutamide (63612-50-0) used for?

Used in Pharmaceutical Industry:
Nilutamide is used as an anti-androgen for the treatment of metastatic prostate cancer. It is particularly effective when used in combination with surgical castration, helping to manage the condition and improve the quality of life for patients.
Used in Oncology:
Nilutamide is used as a therapeutic agent in oncology, specifically for the management of prostatic carcinoma. Its anti-androgen properties make it a valuable tool in combating the progression of prostate cancer and extending the survival rate of patients.
Used in Drug Development:
As a pharmaceutical candidate, Nilutamide is used in the development of new drugs for the treatment of prostate cancer. Its chemical properties and effectiveness in managing prostatic carcinoma make it a promising compound for further research and development in the field of oncology.

Clinical trials with nilutamide were conducted predominantly in combination with orchiectomy. Results indicated retardation of disease progression and relief of metastatic bone pain in patientswith advanced prostate cancer.However, patient survival benefit was small compared with castration alone. Studies of nilutamide monotherapy or combination with LHRH agonists did not have sufficient patient numbers to allow reliable conclusions on efficacy. Nilutamide was first launched in France in 1987 for treatment of metastatic prostate cancer in adjuvant therapy with surgical castration. Approval in several major markets was granted in the following years. The tolerability profile of nilutamide was similar to that of flutamide. Hot flushes, nausea, diarrhea, constipation, gastrointestinal pain, abnormal liver function, and gynecomastia were frequently reported adverse events with both drugs. Additional side effects were predominantly associated with nilutamide treatment: interstitial pneumonitis, impaired adaptation to darkness, and alcohol intolerance. The nonsteroidal anti-androgens flutamide and nilutamide established combined androgen blockade as first-line treatment for metastatic prostate cancer. Still, there was room for improvement with regard to overall survival (OS) and tolerability.

InChI:InChI=1/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)

Relevant articles related to Nilutamide:

Article

Source

Novel androgen receptor degradation agent, preparation method and medical application

-

Paragraph 0018-0019; 0032-0034, (2021/06/26)

5.Buy Nilutamide with the best price .

Shijiazhuang Shuliang commerce trade Co., Ltd. is a quality supplier of Nilutamide. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Nilutamide 63612-50-0.

*Product Name
CasNo
Purity
Quantity
Company name
*Email
*Other Description
*Verification code:
Submit
Purchase Posted Successfully, our staff will contact you within 24 hours.